We are delighted to announce that Oneness Biotech Co. Ltd has become a two-year sponsor of the EWMA Reimbursement Report for 2026 and 2027.
Oneness Biotech is a leading Taiwan-based biopharmaceutical company with a diverse new drug pipeline targeting unmet medical needs. While widely recognized for their advancements in wound healing, their innovative R&D also extends into complex areas such as immunology and metabolic diseases.
This commitment to evidence-based medicine, starting with their growing international presence in wound care, aligns perfectly with EWMA’s mission to improve patient outcomes and access to effective therapies across Europe.
We look forward to this valuable collaboration over the coming years!
Exciting Partnership Announcement!
We are delighted to announce that Oneness Biotech Co. Ltd has become a two-year sponsor of the EWMA Reimbursement Report for 2026 and 2027.
Oneness Biotech is a leading Taiwan-based biopharmaceutical company with a diverse new drug pipeline targeting unmet medical needs. While widely recognized for their advancements in wound healing, their innovative R&D also extends into complex areas such as immunology and metabolic diseases.
This commitment to evidence-based medicine, starting with their growing international presence in wound care, aligns perfectly with EWMA’s mission to improve patient outcomes and access to effective therapies across Europe.
We look forward to this valuable collaboration over the coming years!